151 related articles for article (PubMed ID: 28066787)
1. BCR/ABL can promote CD19
Li D; Zhao X; Zhang R; Jiao B; Liu P; Ren R
Stem Cell Investig; 2016; 3():85. PubMed ID: 28066787
[TBL] [Abstract][Full Text] [Related]
2. Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Maifrede S; Magimaidas A; Sha X; Mukherjee K; Liebermann DA; Hoffman B
Oncotarget; 2017 Sep; 8(41):69281-69294. PubMed ID: 29050203
[TBL] [Abstract][Full Text] [Related]
3. Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.
Yin Z; Su R; Ge L; Wang X; Yang J; Huang G; Li C; Liu Y; Zhang K; Deng L; Fei J
Int J Biol Sci; 2023; 19(4):1211-1227. PubMed ID: 36923939
[TBL] [Abstract][Full Text] [Related]
4. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Krause DS; Lazarides K; von Andrian UH; Van Etten RA
Nat Med; 2006 Oct; 12(10):1175-80. PubMed ID: 16998483
[TBL] [Abstract][Full Text] [Related]
5. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
6. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
8. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
9. Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL.
Hu J; Feng M; Liu ZL; Liu Y; Huang ZL; Li H; Feng WL
Tumour Biol; 2016 Nov; ():. PubMed ID: 27817074
[TBL] [Abstract][Full Text] [Related]
10. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
11. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
12. Induction of Chronic Myeloid Leukemia in Mice.
Zhang H; Li S
Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135
[TBL] [Abstract][Full Text] [Related]
13. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
[TBL] [Abstract][Full Text] [Related]
14. B-lymphoid/myeloid stem cell origin in Ph-positive acute leukemia with myeloid markers.
Akashi K; Taniguchi S; Nagafuji K; Harada M; Shibuya T; Hayashi S; Gondo H; Niho Y
Leuk Res; 1993 Jul; 17(7):549-55. PubMed ID: 8326735
[TBL] [Abstract][Full Text] [Related]
15. IGF-IR determines the fates of BCR/ABL leukemia.
Xie J; Chen X; Zheng J; Li C; Stacy S; Holzenberger M; Hu X; Zhang CC
J Hematol Oncol; 2015 Feb; 8(1):3. PubMed ID: 25648584
[TBL] [Abstract][Full Text] [Related]
16. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia.
Thijsen SF; van Oostveen JW; Schuurhuis GJ; Theijsmeijer AP; Oudejans CB; van Wijk IJ; Langenhuijsen MM; Ossenkoppele GJ
Leukemia; 1997 Oct; 11(10):1762-8. PubMed ID: 9324298
[TBL] [Abstract][Full Text] [Related]
18. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
19. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
Dugray A; Geay JF; Foudi A; Bonnet ML; Vainchenker W; Wendling F; Louache F; Turhan AG
Leukemia; 2001 Oct; 15(10):1658-62. PubMed ID: 11587226
[TBL] [Abstract][Full Text] [Related]
20. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]